Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO) A protocol amendment limited enrolment to patients with epidermal growth factor receptor (EGFR) histoscore ≥200 and closed the CIL-twice arm for practical feasibility issues. Primary end point was progression-free survival (PFS; independent read); secondary end points included overall survival (OS), safety, and biomarker analyses. A comparison between the CIL-once and control arms is reported, both for the total cohorts, as well as for patients with EGFR histoscore ≥200.
introduction Platinum-based combination chemotherapy remains the cornerstone of treatment in advanced, non-oncogene-driven non-small-cell lung cancer (NSCLC), resulting in median survival times of 8-11 months [1] . More recently, addition of targeted agents to platinum doublet chemotherapy has been studied in numerous phase III trials. Only a few of these have reported an overall survival (OS) benefit, e.g. the ECOG 4599 study with bevacizumab [hazard ratio (HR) 0.79; P = 0.003] [2] and the FLEX study with cetuximab (HR 0.87; P = 0.044 [3] ).
Targeting integrin signalling in conjunction with platinumbased chemotherapy is an interesting treatment option in NSCLC. Integrins are a family of transmembrane receptors that regulate interactions between the tumour and its microenvironment. There are 24 different types, based on a heterodimerization of 18 α and 8 β subunits. Integrins play a crucial role in cell-cell adhesion and in the invasiveness and/or metastasizing potential of NSCLC cells [4] . Other key functions include regulation and activation of growth factors, and the downstream signalling of tyrosine kinases leading to angiogenesis, proliferation and cell survival. Integrins are also directly involved in angiogenesis [5] . For NSCLC, integrin expression has been reported in tumour cells, matrix, and accompanying angiogenesis [6] .
Integrin inhibitors are divided into three classes: monoclonal antibodies, oral small-molecule inhibitors, and small peptides. Cilengitide (EMD 121974) is a small peptide that was in an advanced developmental phase in the glioblastoma setting when development started in NSCLC [7] . This cyclic pentapeptide is a selective, competitive inhibitor of αvβ3 and αvβ5 integrins to matrix substances such as vitronectin, fibronectin, fibrinogen, osteopontin, and others [8] . In pre-clinical studies, cilengitide exhibited synergistic action with different cytotoxic agents, including cisplatin and cetuximab [8] .
In a phase I trial in patients with recurrent malignant glioma, single-agent cilengitide-administered i.v. twice-weekly-proved to be safe up to doses of 2400 mg/m 2 and resulted in durable responses [9] . In a follow-up, randomized phase II study in patients with newly diagnosed glioblastoma multiforme, a dose of 2000 mg cilengitide gave superior results to 500 mg cilengitide when combined with radiation and temozolomide, and exhibited a good tolerability profile [10] . Another phase II study, which compared twice-weekly doses of 500 or 2000 mg single-agent cilengitide in patients with relapsing glioblastoma, confirmed the drug's very low toxicity profile. Modest antitumor activity was noted, mostly in the 2000-mg arm [11] . Based on these data, cilengitide was the first integrin inhibitor to enter phase III clinical trial testing in combination with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma (CENTRIC study, NCT00689221).
This phase II randomized study (NCT00842712) evaluated the safety and efficacy of adding cilengitide to platinum-based chemotherapy and cetuximab as first-line treatment in patients with advanced NSCLC. [3] . Gemcitabine was also allowed due to the decreased usage of vinorelbine; pemetrexed was not chosen due to its unsuitability for all NSCLC patients. At the end of chemotherapy, patients continued with once-weekly cetuximab and cilengitide until radiographically documented progressive disease, unacceptable toxicity, or withdrawal of consent. Patients who discontinued treatment without progressive disease remained on study, with response assessment every 6 weeks until disease progression or commencement of another antitumor treatment. Enrolment commenced in February 2010. In December 2010, data from the large FLEX trial [12] indicating that epidermal growth factor receptor (EGFR) expression is a potential biomarker led to a protocol amendment (see supplementary Methods, available at Annals of Oncology online). The study focus and inclusion criteria changed to enrol only patients with EGFR histoscore ≥200, who were expected to benefit most from the addition of cetuximab to platinum-based chemotherapy. In the same amendment, the CIL-twice arm was closed for inclusion for practical feasibility reasons. Patients randomized to CIL-twice before the amendment (51 patients) could continue their treatment as planned.
outcome measures
The primary efficacy end point was independent review committee (IRC)-assessed progression-free survival (PFS), defined as time in months from randomization day to first observation of radiologically confirmed disease progression or death. A pre-specified sensitivity analysis was carried out using an investigator read of tumour response. Secondary end points were OS, safety, and biomarker analysis. The total intent-to-treat (ITT) analysis set, which included all patients randomized to treatment, was used for the efficacy analyses. Efficacy was assessed using the Kaplan-Meier product-limit method. HRs including 95% confidence intervals (CI) of the CIL-once relative to the control arm were calculated using Cox's proportional hazards model stratified by the first-line chemotherapy. In the efficacy, comparison between CIL-once and control, patients with EGFR histoscore ≥200 and with EGFR histoscore <200 were considered as subgroups of the ITT analysis set. The sample size considerations, pre-and post-amendment, are detailed in the supplementary Methods, available at Annals of Oncology online.
Safety analyses were carried out using the safety analysis set, which included all patients who received any dose of cilengitide, cetuximab, or chemotherapy. Adverse events (AEs) were summarized according to the Medical Dictionary for Regulatory Activities terms and their severity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 3.0).
EGRF and integrin biomarker analysis
Formalin-fixed and paraffin-embedded tumour samples were collected from patients. EGFR expression was determined using the EGFR pharmDx™ Kit (Dako; Glostrup, Denmark) following the manufacturer's protocol. Similar patient material was used to determine the expression of integrins αvβ3 and αvβ5 on tumour cells and endothelial cells to investigate their predictive value in PFS and OS. Further details are given in the supplementary Methods, available at Annals of Oncology online [13] . Expression readouts, referred to as histoscores, range from 0 to 300. results patients A total of 220 patients were randomly assigned, 85 of these to the CIL-once arm, 51 to CIL-twice arm (closed at amendment), and 84 to the control arm. In total, 215 received at least one dose of trial medication and comprised the safety analysis set (Figure 1 ). This publication reports the results from the CILonce and control arms. The CIL-twice cohort was not included as early closure meant the arm was not enriched for patients with high EGFR expression, and the target sample size was not reached. Patient demographics and baseline characteristics were well balanced between the arms (Table 1) .
efficacy
The primary efficacy end point, IRC-assessed median PFS, was 6.2 months (95% CI 5.6-7.4) in the CIL-once arm versus 5.0 months (95% CI 4.2-5.6) in the control arm (HR 0.718; 95% CI 0.492- (Figure 2A ). For patients with EGFR ≥200, the PFS was 6.8 months in the CIL-once arm compared with 5.6 months in the control arm (HR 0.566; 95% CI 0.323-0.993; P = 0.0446; Figure 2B ). Among patients with EGFR histoscore <200, median PFS was 7.1 months in the CIL-once arm versus 3.2 months in the control arm; high variability was observed due to the low subgroup size (HR 0.731; 95% CI 0.372-1.438; P = 0.3628). In the pre-specified sensitivity analyses, PFS (investigator read) was 5.6 months for CIL-once versus 5.3 months for control (HR 0.909; 95% CI 0.642-1.286; P = 0.5912), and 5.8 versus 5.5 months (HR 0.980; 95% CI 0.603-1.593; P = 0.9348) for patients with EGFR ≥200. Among patients with EGFR <200, PFS was 6.5 months in the CIL-once versus 3.2 months in the control arm (HR 0.814; 95% CI 0.424-1.560; P = 0.5348). PFS subgroup analysis (supplementary Figure S1A , available at Annals of Oncology online) showed a non-significant trend toward improved response to cilengitide in patients with squamous cell cancer (HR 0.52; 95% CI 0.22-1.19) versus those with adenocarcinoma or other histologies. Females and patients ≥65 years tended to benefit more from CIL-once treatment compared with chemotherapy treatment only (HR 0.45; 95% CI 0.23-0.87, and HR 0.33; 95% CI 0.13-0.84, respectively). Figure 2A shows the overall ITT population; Figure 2B shows the ITT population for patients with EGFR ≥200. CI, confidence interval; CIL, cilengitide; HR, hazard ratio; IRC, independent review committee; EGFR, epidermal growth factor receptor; ITT, intent-to-treat; PFS, progression-free survival.
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Median OS was numerically longer, at 13.6 months in the CIL-once arm versus 9.7 months in the control arm (HR 0.813; 95% CI 0.564-1.171; P = 0.2648; Figure 3A ). For patients with high EGFR expression, median OS was similar in the CIL-once (13.2 months) and control arms (11.8 months; HR 0.952; 95% CI 0.561-1.614; P = 0.855; Figure 3B ). Among patients with lower EGFR scores, median OS was longer in the CIL-once arm (14.3 months) versus control (8.6 months; HR 0.814; 95% CI 0.411-1.616; P = 0.5564). The OS subgroup analysis revealed no trends in subgroups (supplementary Figure S1B , available at Annals of Oncology online).
safety
The AE distribution was similar between CIL-once versus control in terms of any AE (both 100%), any NCI CTCAE toxicity grade 3 or 4 (84.7% versus 88.8%), study treatment-related (94.1% versus 95.0%), or study treatment-related NCI CTCAE toxicity grade 3 or 4 (70.6% versus 71.3%) AE. The most common AEs of any grade, regardless of relationship, which occurred more frequently in the CIL-once arm included nausea, neutropenia, and anaemia (Table 2) . Cilengitide treatment did not increase the proportion of patients experiencing haemorrhage (in fact it was lower, 18.8% versus 26.3%) or thromboembolic events (31.8% 
biomarker analysis
Thirty-six patients in the CIL-once arm and 40 patients in the control arm were included in the biomarker analysis, with similar demographics between the two patient groups (data not shown). The distribution of biomarkers was comparable between the groups. Patients in both arms exhibited very low positive signals for αvß3-expressing tumours. Table 3 summarizes the expression of the biomarkers linked to OS and PFS; the sample size did not permit correlations to be made between expression level of the biomarkers and PFS, OS, or prediction of clinical benefit.
discussion
The addition of an integrin inhibitor to conventional anticancer therapy has been a promising avenue, given the crucial role of integrins in tumour regulation. A multicentre, phase II randomized study in patients with relapsing NSCLC explored three doses of single-agent cilengitide (240, 400, or 600 mg/m 2 i.v. twice-weekly) with second-line docetaxel chemotherapy [14] . Median PFS was 54, 63, 63, and 67 days for cilengitide 240, 400, and 600 mg/m 2 , and docetaxel 75 mg/m 2 , respectively. One-year OS rates were 13%, 13%, 29%, and 27%, respectively. While this study was exploratory, without statistical comparisons, these data were the basis for further development of cilengitide in NSCLC and led to the phase II randomized CERTO trial.
Initially, CERTO was a three-arm trial. Upon the availability of the EGFR histoscore data from the FLEX trial [12] , it was decided following in-depth discussions to limit further recruitment to patients with high (≥200) EGFR histoscore, and to close the twice-weekly arm because of feasibility for patients. The results presented herein summarize the data for patients assigned to the CIL-once and control arms. The CILtwice arm, which was closed following the protocol amendment, was not included as the arm was not enriched for patients with high EGFR expression, and the target sample size was not achieved, hence no valid comparisons could be made with the two other arms. CERTO delivered a non-significant trend toward improvement in the primary end point, median PFS per independent read, with a HR of 0.718 (95% CI 0.492-1.048; P = 0.0845). This trend in PFS was more pronounced in the subpopulation of patients with high EGFR expression, with a HR of 0.566 (95% CI 0.323-0.993; P = 0.0446). The differences in PFS per independent read were not translated to significant OS differences. The safety profile of the combination of cilengitide with cetuximab and platinum-based chemotherapy was as expected. Cilengitide treatment resulted in no additional toxicity or safety concerns, compared with the control arm. In particular, there was no evidence to suggest that cilengitide treatment increased the risk of bleeding or thromboembolic events. Exploratory biomarker analyses consisted of immunohistochemical staining for αvß3 and αvß5 integrins on endothelial and tumour cells. This analysis suggested the presence of these biomarkers, although neither was prognostically correlated with PFS or OS, nor predictive of a treatment effect for cilengitide. However, the sample size prevented true interpretation of these data, so this analysis should be carried out in a larger population.
Unfortunately, the pivotal phase III trial in glioblastoma did not deliver the anticipated patient benefit. In the study, 545 patients with newly diagnosed glioblastoma were 1:1 randomly assigned to cilengitide or control added to standard temozolomide chemoradiotherapy between 31 October 2008, and 12 May 2011 [15] . There was no overall additional toxic effect from cilengitide, but OS curves overlapped, with a median OS of 26.3 months for both groups. Consequently, further development of cilengitide as an anticancer drug was terminated.
In conclusion, in the CERTO study, a trend toward potentially improved PFS for cilengitide versus control was noted in patients with advanced NSCLC. However, based on data in the glioblastoma setting, the cilengitide programme was closed, and no further studies will be conducted in NSCLC. Moreover, the inconsistent sensitivity analyses (independent-versus investigator-read PFS), lack of OS benefit, and the complexity of the trial induced by the major protocol amendment following the release of the EGFR histoscore data in relation to cetuximab did not suggest that cilengitide would be a step forward in the treatment of NSCLC. Nevertheless, integrins remain a potentially interesting therapeutic target, and other integrin-blocking compounds are under investigation to further define their role in advanced NSCLC.
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